Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN12 | Q05209 | 1/20 | 0.77 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.77 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.70 |
| ▸ | MMP3 | P08254 | 2/20 | 0.70 |
| ▸ | MMP13 | P45452 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | GFER | P55789 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10491513 | 1.00 | PTPN12 (0.77) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL6886567 | 1.00 | PTPN12 (0.77) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL30250172 | 0.96 | PTPN12 (0.72) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL439556 | 0.93 | PTPN12 (0.67) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL25207676 | 0.89 | PTPN12 (0.69) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL25997484 | 0.88 | AKR1B1 (0.83) | AKR1B1PTPN1MMP3MMP13KMT2A | |
| SCHEMBL25992865 | 0.88 | MEN1 (0.68) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL10492188 | 0.88 | PTPN12 (0.79) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL10492208 | 0.88 | PTPN12 (0.79) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL14652602 | 0.88 | PTPN12 (0.79) | PTPN12PTPN22AKR1B1PTPN1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206412-B2 | Thioxothiazolidine inhibitors | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-6673816-B1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | Esswein, Angelika (DE) | 2004-01-06 | — | — | US | disclosed |
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD | 2003-02-13 | — | — | US | disclosed |
| EP-1117655-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | Esswein, Angelika (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018747-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | NR1H4, NR1D1, NR1I2 | PTPN12 3368/4885PTPN22 3165/4885AKR1B1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.